ライフサイエンスコーパス: Wegener's granulomatosis

1 s and granulomatosis with polyangiitis (GPA, Wegener's granulomatosis).

2 lyangiitis and glomerulonephritis (excluding Wegener's granulomatosis).

3 matosis with polyangiitis, formerly known as Wegener's granulomatosis.

4 se and Henoch-Schonlein purpura, and A1AT in Wegener's granulomatosis.

5 damage and its relevance to the diagnosis of Wegener's granulomatosis.

6 on specific forms of damage associated with Wegener's granulomatosis.

7 s an important concern for all patients with Wegener's granulomatosis.

8 tant source of morbidity among patients with Wegener's granulomatosis.

9 One of them is Wegener's granulomatosis.

10 phil cytoplasmic antibodies in patients with Wegener's granulomatosis.

11 itis led to an initial mistaken diagnosis of Wegener's granulomatosis.

12 have been implicated in the pathogenesis of Wegener's granulomatosis.

13 gham Vasculitis Activity Score, modified for Wegener's granulomatosis.

14 ission induction agent for severe refractory Wegener's granulomatosis.

15 y may play a role in the etiopathogenesis of Wegener's granulomatosis.

16 ical diagnosis was suggested to be a type of Wegener's granulomatosis.

17 45 transplant recipients and 1 patient with Wegener's granulomatosis.

18 e in selected patients with limited forms of Wegener's granulomatosis.

19 es, including aortitis, atherosclerosis, and Wegener's granulomatosis.

20 s in whom leptomeningeal biopsy demonstrated Wegener's granulomatosis.

21 hospitalizations among 571 individuals with Wegener's granulomatosis.

22 rate efficacy in severe vasculitis or severe Wegener's granulomatosis.

23 n estimated 10,771 hospitalizations included Wegener's granulomatosis among the discharge diagnoses.

24 A 62-year-old male with a history of Wegener's granulomatosis and immunosuppressive therapy p

25 ologists are often in a position to diagnose Wegener's granulomatosis and prevent significant morbidi

26 data suggest a familial link between risk of Wegener's granulomatosis and rheumatoid arthritis.

27 d previously unexpected associations between Wegener's granulomatosis and the incidence of malignancy

28 matosis with polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis.

29 ligand for PECAM-1 and it may have a role in Wegener's granulomatosis, and antibodies to HNA-2a frequ

30 pears to be useful in preventing relapses in Wegener's granulomatosis, and patients develop fewer inf

31 rcoidosis, systemic lupus erythematosus, and Wegener's granulomatosis are also reported.

32 ifferences in the geographic distribution of Wegener's granulomatosis are apparent when analysis cons

33 logic imaging patterns of orbital disease in Wegener's granulomatosis are presented.

34 Granulomatous syndromes, such as Wegener's granulomatosis, are defined according to compl

35 ath certificates in the United States listed Wegener's granulomatosis as a cause of death.

36 We describe a patient who presented with Wegener's granulomatosis associated with antineutrophil

37 New diagnosis of Wegener's granulomatosis at baseline was an independent

38 Controversy has arisen over the eponym Wegener's granulomatosis because of alleged involvement

39 The syndrome resembles Wegener's granulomatosis both clinically and histologica

40 ined as Birmingham Vasculitis Activity Score/Wegener's Granulomatosis (BVAS/WG)=0 off prednisone.

41 on (Birmingham Vasculitis Activity Score for Wegener's granulomatosis [BVAS/WG] score of 0) at month

42 This case illustrates that Wegener's granulomatosis can cause chronic meningitis.

43 icate certain systemic conditions, including Wegener's granulomatosis, Cogan's syndrome, polyarteriti

44 se 3, a biomarker for the autoimmune disease Wegener's granulomatosis, diluted up to 10(7)-fold in 1%

45 During the Wegener's Granulomatosis Etanercept Trial (WGET), a plac

46 d solid malignancies was observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which

47 We evaluated data from the Wegener's Granulomatosis Etanercept Trial.

48 This study used the BVAS/WG data from the Wegener's Granulomatosis Etanercept Trial.

49 Although studies of Wegener's granulomatosis frequently focus on controlling

50 teritis nodosa, hypersensitivity vasculitis, Wegener's granulomatosis, giant cell arteritis and Takay

51 tain forms of systematic vasculitis, such as Wegener's granulomatosis, have circulating antineutrophi

52 specificity; for example, most patients with Wegener's granulomatosis in China have myeloperoxidase-a

53 Other genes associated with Wegener's granulomatosis in replicated candidate gene st

54 The prevalence of Wegener's granulomatosis in the United States is approxi

55 roscopic polyangiitis (P = 2.9 x 10(-4)) and Wegener's granulomatosis in two independent cohorts from

56 e, and to have systemic lupus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or poly

57 Wegener's granulomatosis is a multisystem disease charac

58 ase 3 (PR3), the major target autoantigen in Wegener's granulomatosis is a serine proteinase that is

59 amount of evidence supports the notion that Wegener's granulomatosis is an autoimmune disease.

60 Standard therapy for Wegener's granulomatosis is fraught with substantial tox

61 th the characteristic granuloma formation of Wegener's granulomatosis is unclear.

62 of granulomatosis with polyangiitis (GPA; or Wegener's granulomatosis) is the granulomatous inflammat

63 hic arthritis, systemic lupus erythematosis, Wegener's granulomatosis, juvenile dermatomyositis, juve

64 ic of the subset of vasculitis that includes Wegener's granulomatosis, microscopic polyangiitis (micr

65 ondary to microscopic polyangiitis (n=43) or Wegener's granulomatosis (n=42).

66 olled 197 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis.

67 flammatory diseases such as Crohn's disease, Wegener's granulomatosis, or sarcoidosis.

68 erity may vary considerably in patients with Wegener's granulomatosis, polyarteritis nodosa, microsco

69 oid arthritis, systemic lupus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis,

70 omatosis with polyangiitis (GPA), previously Wegener's granulomatosis, requires prompt diagnosis and

71 Within the Wegener's granulomatosis subgroup, the median VDI score

72 y to proteinase 3 and neutrophil elastase in Wegener's granulomatosis, support the concept that there

73 In particular, in contrast to Wegener's granulomatosis, the need for routine cyclophos

74 0,000 hospitalizations/year in patients with Wegener's granulomatosis to 2 cases/10,000 hospitalizati

75 Patients with Wegener's granulomatosis usually seek medical care for r

76 A diagnosis of Wegener's granulomatosis was considered in all of them,

77 Wegener's granulomatosis was initially considered to be

78 Patients with Wegener's granulomatosis were excluded.

79 ic markers for the small vessel vasculitides Wegener's granulomatosis (WG) and microscopic polyangiit

80 Wegener's granulomatosis (WG) and microscopic polyangiit

81 Wegener's granulomatosis (WG) is a granulomatous vasculi

82 Wegener's granulomatosis (WG) is a systemic inflammatory

83 Wegener's granulomatosis (WG) is a systemic vasculitis o

84 The precipitating event(s) that triggers Wegener's granulomatosis (WG) is unknown.

85 is report describes a case of severe limited Wegener's granulomatosis (WG) presenting in the third tr

86 nfection, chronic hepatitis C infection, and Wegener's granulomatosis (WG), an inflammatory, granulom

87 ccompany the neutrophilic vasculitis seen in Wegener's granulomatosis (WG), are directed against prot

88 T) may be a determinant of susceptibility to Wegener's granulomatosis (WG).

89 She was initially thought to have Wegener's granulomatosis (WG).

90 tients with CIMDL with that in patients with Wegener's granulomatosis (WG).

91 neutrophil cytoplasmic antibodies (ANCAs) in Wegener's granulomatosis (WG).

92 phil cytoplasmic antibody (cANCA)-associated Wegener's granulomatosis (WG).

93 bodies in approximately 60% of patients with Wegener's granulomatosis (WG).

94 Total PSV, subgroups (47 Wegener's granulomatosis [WG], 12 microscopic polyangiit